Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Merkel Cell Carcinoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab 400mg IV

DRUG

Lutetium Lu 177 dotatate

7.4GBq (200 mCi) IV

Trial Locations (3)

RECRUITING

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors

lead

Weill Medical College of Cornell University

OTHER